Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sodium Fluorescein Clear all
Not listed Phase 4 Interventional

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

NCT02478346
View directory record Official record
Conditions
Cerebrovascular Disorders, Intracranial Neoplasms
Interventions
Fluorescein Sodium
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505
View directory record Official record
Conditions
Uveitis
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 17, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational

Establishment of Biomarkers for Fabry Disease

NCT01165697
View directory record Official record
Conditions
Fabry Disease
Interventions
Fluorescein angiography
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

NCT00411333
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide (Kenalog)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Not applicable Interventional

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

NCT05231278
View directory record Official record
Conditions
Lung Neoplasms
Interventions
nCLE aided RANB biospy
Device
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Concord, California • Altoona, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

NCT00457067
View directory record Official record
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

NCT01268306
View directory record Official record
Conditions
Keratitis
Interventions
B+L Biotrue MPS and B+L PureVision
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 17, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

Kidney Precision Medicine Project

NCT04334707
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
Interventions
Kidney Biopsy, MRI, Retina Scan
Procedure · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

NW500 Non-Mydriatic Retinal Camera Clinical Performance Study

NCT05286502
View directory record Official record
Conditions
Fundus Photography
Interventions
fundus photography
Device
Lead sponsor
Topcon Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multimodal Ocular Imaging in Neurodegeneration

NCT03699644
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
Interventions
Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
Device · Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Eyelid Androgen Treatment in Dry Eye

NCT06154200
View directory record Official record
Conditions
Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions
Testosterone gel 4.5%, Vehicle gel
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NVAMD Satellite Study

NCT02251366
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Physician-guided diagnostic
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

NCT00764738
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
Device · Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 17, 2026, 1:09 AM EDT
Completed No phase listed Observational

Digital Photography to Evaluate Dry Eye

NCT00073099
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

NCT04351373
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Fluorescein Sodium, YELLOW560 filter
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 17, 2026, 1:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

NCT03228407
View directory record Official record
Conditions
Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
Interventions
Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
Procedure · Diagnostic Test
Lead sponsor
McGuire Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 17, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes

NCT07270133
View directory record Official record
Conditions
Diabetic Retinal Disease
Interventions
Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography
Diagnostic Test · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 1:09 AM EDT
Completed Not applicable Interventional

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

NCT02857374
View directory record Official record
Conditions
Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Sentinel Lymph Node Biopsy
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 17, 2026, 1:09 AM EDT